| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Friday’s Close |
|---|---|---|---|---|---|
| AGN | Allergan plc. | $184.29 | $62.56B | N/A |
Edwards Lifesciences (EW) Q2 Earnings: Will It Be a Miss?
http://www.zacks.com/stock/news/223858/edwards-lifesciences-ew-q2-earnings-will-it-be-a-miss?cid=CS-ZC-FT-223858
Jul 18, 2016 - Edwards (EW) has a Zacks Rank #4 (Sell), which along with a negative ESP of -1.43% makes surprise prediction difficult.
0
Top 7 Research Reports for July 15, 2016
http://www.zacks.com/research-daily/86015/top-7-research-reports-for-july-15-2016?cid=CS-ZC-FT-86015
Jul 15, 2016 - Top 7 Research Reports for July 15, 2016
0
Teva (TEVA) Provides 2016-2019 Outlook, Shares Gain
http://www.zacks.com/stock/news/223394/teva-teva-provides-2016-2019-outlook-shares-gain?cid=CS-ZC-FT-223394
Jul 14, 2016 - Teva (TEVA) provided its preliminary outlook for 2016-2019 and expects the Actavis Generics acquisition to go through anytime soon.
0
Why are Allergan (AGN) and Teva Pharma (TEVA) Stocks Up Today?
http://www.zacks.com/stock/news/223342/why-are-allergan-agn-and-teva-pharma-teva-stocks-up-today?cid=CS-ZC-FT-223342
Jul 13, 2016 - On Wednesday, shares of Allergan (AGN) and Teva Pharmaceuticals (TEVA) are both on the rise, up around 2% and 3%, respectively, in morning trading after Teva CEO Erez Vigodman said it expects its $40.5 billion acquisition of Allergan's generics business to close any day.
0
Teva Raises Q2 Guidance; to Unveil 2016-2019 View
http://www.zacks.com/stock/news/223261/teva-raises-q2-guidance-to-unveil-2016-2019-view?cid=CS-ZC-FT-223261
Jul 13, 2016 - Ahead of its acquisition of Allergan's Generics business, Teva Pharmaceutical (TEVA) raised its second-quarter 2016 guidance for earnings and revenues.
0
Allergan's (AGN) CEO Brent Saunders on Business Update Conference Call (Transcript)
http://seekingalpha.com/article/3963629-allergans-agn-ceo-brent-saunders-business-update-conference-call-transcript?source=feed_tag_transcripts
Apr 06, 2016 - Allergan PLC (NYSE:AGN) Business Update Conference Call April 06, 2016 10:00 AM ET Executives Lisa DeFrancesco - VP, IR Brent Saunders - CEO & President Paul Bisaro - Executive Chairman Tessa Hila
0
KYTHERA Files IND Application for Male Hair Loss Treatment
http://www.zacks.com/stock/news/191164/kythera-files-ind-application-for-male-hair-loss-treatment?cid=CS-ZC-FT-191164
Sep 23, 2015 - KYTHERA (KYTH) has filed an investigational new drug application for KYTH-105 for the treatment of male pattern hair loss.
0
Allergan/Gedeon's Vraylar Gets FDA Nod for Mental Disorders
http://www.zacks.com/stock/news/190652/allergan-gedeons-vraylar-gets-fda-nod-for-mental-disorders?cid=CS-ZC-FT-190652
Sep 18, 2015 - Allergan (AGN) and Gedeon Richter Plc. announced that the FDA has approved Vraylar for the treatment of bipolar I disorder and schizophrenia in adults.
0
Apricus Up after Regaining Vitaros U.S. Rights from Allergan
http://www.zacks.com/stock/news/189832/apricus-up-after-regaining-vitaros-us-rights-from-allergan?cid=CS-ZC-FT-189832
Sep 11, 2015 - Apricus Biosciences' (APRI) shares gained 7.7% after the company regained the U.S. development and commercialization rights to Vitaros from Allergan.
0
Apricus Biosciences (APRI) Looks Good: Stock Jumps 7.7%
http://www.zacks.com/stock/news/189719/shares-of-apricus-biosciences-apri-rose-roughly-8in-the-last-session?cid=CS-ZC-FT-189719
Sep 11, 2015 - Apricus Biosciences (APRI) was a big mover last session with its shares rising roughly 8% on the day.
0